| (Values in U.S. Thousands) | Dec, 2020 | Sep, 2020 | Jun, 2020 | Mar, 2020 | Dec, 2019 |
| Sales | 50,080 | 42,650 | 40,090 | 38,740 | 27,200 |
| Sales Growth | +17.42% | +6.39% | +3.48% | +42.43% | +30.02% |
| Net Income | -3,720 | -3,230 | -4,680 | -7,010 | -10,290 |
| Net Income Growth | -15.17% | +30.98% | +33.24% | +31.88% | +11.90% |
Genmark Diagnostics (GNMK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor' XT-8 system is the second generation in GenMark Dx's eSensor' platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.
Fiscal Year End Date: 12/31